CYTK · Cytokinetics
The AI's read
That gives Cytokinetics more ways to grow Mycorzo sales. U.S. prescribing is rising, and Germany is its first European market. Successful aficamten results could help reach another group of patients, but regulators must still review the drug. Higher launch costs and the public offering's possible effect on existing owners temper the gains. Commercial progress and the trial results carry more weight in this report.